Efficacy of RGLS4326 in Human Primary 3D-Cyst Cultures Derived from Autosomal Dominant Polycystic Kidney Disease (ADPKD) Donors. Efficacy of RGLS4326 in Human Primary 3D-Cyst Cultures Derived from Autosomal Dominant Polycystic Kidney Disease (ADPKD) Donors Post navigation Previous: Quality of Life Changes in Patients with Alport Syndrome: Results from the ATHENA StudyNext: Urine and blood biomarkers correlate with rate of eGFR decline in Alport syndrome: The ATHENA Study
Efficacy of RGLS4326 in Human Primary 3D-Cyst Cultures Derived from Autosomal Dominant Polycystic Kidney Disease (ADPKD) Donors
